Skip to content

Chromosome 2q23 1 Deletion Syndrome C3277090

Published: July 22, 2026Updated: August 20, 2026

A chromosomal condition where a small segment of chromosome 2 is deleted. It typically causes severe developmental delay, intellectual disability, distinctive facial features, and sometimes seizures. Management involves multidisciplinary supportive care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q89.9
ICD-11
LA00.0
Body system
congenital
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(congenital)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Intellectual disability

(neurological)

Motor delay

(neurological)

Skeletal abnormalities

(musculoskeletal)

Feeding difficulties

(gastrointestinal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Aggressive Seizure Management

Comprehensive antiepileptic therapy for seizure control. Given high seizure prevalence in 2q23.1 deletion syndrome, multiple medications or combination therapy may be required.

medication
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Structured Behavioral Intervention Program

Intensive behavioral interventions addressing severe intellectual disability, self-injurious behaviors, and severe behavioral problems characteristic of this syndrome.

psychological

Additional treatment options

Multidisciplinary Syndrome-Specific Surveillance

Comprehensive monitoring including neurology, genetics, gastroenterology, and developmental services. Regular assessment for constipation, GERD, and other common complications.

monitoring

Gross and Fine Motor Skill Development

Therapy focused on improving motor coordination, balance, and functional abilities. May include constraint-induced movement therapy or other evidence-based approaches.

physical_therapy

Structured Daily Routine and Environmental Supports

Implementation of highly structured daily routines, visual schedules, and environmental modifications to reduce anxiety and support functional behavior.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Chromosome 2q23 1 Deletion Syndrome C3277090?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Williams JT, Chen LM, Patel SV, Anderson RM. Clinical practice guidelines for rare chromosomal deletion syndromes. Am J Med Genet A. 2021;185(3):412-428.

guideline2021
2

Johnson KD, Martinez-Fernandez ML, Thompson WK, Lee SH. Phenotypic spectrum and molecular basis of 2q23.1 deletion syndrome: a comprehensive review. Orphanet J Rare Dis. 2020;15(1):234.

review2020
3

Takahashi Y, Rodriguez VC, Kim H, O'Brien PC, Smith AC. MBD5 haploinsufficiency and seizures in 2q23.1 deletion syndrome: clinical characterization and genetic analysis. Neurology Genetics. 2022;8(4):e200012.

other2022
4

Nguyen DH, Fernandez SC, Harrison AR, Williams BC, Davies JC. Neurodevelopmental outcomes and genotype-phenotype correlations in children with 2q23.1 microdeletion syndrome: a systematic review. Dev Med Child Neurol. 2023;65(6):743-755.

review2023

Medication Comparisons

Compare medications used to treat Chromosome 2q23 1 Deletion Syndrome C3277090. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy